While the KRASG12C mutation is only found in 3 to 4% of colon carcinoma, it is more prevalent in NSCLC (~14%) and clinical efficacy of the KRAS inhibitors also seems to be higher in lung cancer. This evidence concerns the gene KRAS and lung cancer.